Observational studyBMC infectious diseases2026
Increased mortality and Acinetobacter baumannii predominance despite stable healthcare-associated infection rates during the COVID-19 pandemic.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronavirus disease 2019 (COVID-19), first identified in Wuhan, China, in December 2019, rapidly evolved into a global pandemic with substantial morbidity and mortality. Severe COVID-19 cases, particularly those with pneumonia requiring intensive care unit (ICU) admission, posed significant challenges for healthcare systems. This study aimed to evaluate and compare healthcare-associated infections (HAIs) developing in the ICU during the pre-pandemic and pandemic periods.
methodsThis retrospective observational study was conducted at Sakarya Yenikent State Hospital, a secondary-care hospital with 50 ICU beds. Active surveillance data collected by the infection control team were analyzed for two periods: pre-pandemic (May 2018-February 2020) and pandemic (March 2020-December 2021). The number of ICU patients, patient-days, HAI rates, causative microorganisms, antimicrobial resistance patterns, and mortality rates were compared between periods. Statistical analyses were performed using Epi Info™ version 7.2.5.0, with p < 0.05 considered statistically significant.
resultsA total of 1,840 patients (16,572 patient-days) in the pre-pandemic period and 2,119 patients (12,460 patient-days) in the pandemic period were followed. Mortality significantly increased during the pandemic period compared to the pre-pandemic period (40.96% vs. 24.94%, p = 0.00001). Although the overall HAI rate did not differ significantly between periods (3.26% vs. 2.73%, p = 0.333), Although the overall HAI rate did not differ significantly between periods (3.26% vs. 2.73%, p = 0.333), HAI density was higher during the pandemic. Notably, Acinetobacter baumannii-related HAIs increased significantly during the pandemic period (58.89% vs. 35.00%, p = 0.016), while distributions of other pathogens remained similar. Antimicrobial resistance patterns were more pronounced during the pandemic period.
conclusionDespite similar HAIs rates, in-hospital mortality increased during the pandemic. This was accompanied by higher disease severity, reflected by increased cardiopulmonary resuscitation rates, and a shift toward Acinetobacter baumannii infections. Although mortality was high among COVID-19-positive patients, COVID-19 status was not an independent predictor. Overall, worse outcomes during the pandemic were associated with increased disease severity and pathogen distribution rather than changes in HAI incidence. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.